Chikungunya virus and autoimmunity: Consensus immune epitope analysis between chikungunya virus and arthritis

Ding, Chen; Gen, Miao; Liu, Yangang; Wang, Wen; Qi, Zhongtian

doi:10.1016/j.autrev.2021.102789

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus multiplies within cells, generating new viral proteins, with MHC class I presenting antigens to T CD8+ cells for targeted cell destruction and MHC class II activating T CD4+ cells to influence immune responses through cytokines, controlling infection and inhibiting viral replication [67,86,94]. Research indicates importance of molecular mimicry in CHIKV induced arthritis, revealing shared immune epitopes with human proteins linked to arthritis, such as FLT1, KDR, TIE1, PADI4, FCRL3, PTPN22, and CSK, and suggesting that antibodies targeting these epitopes may contribute to autoimmune responses in CHIKV infection, particularly in the context of arthritis, urging further exploration with suitable animal models [95].…”

Section: Immunology Of Chikungunya Virusmentioning

confidence: 99%

Chikungunya Virus Vaccine: An Update Review

Shaikh,

Faiyazuddin,

Khan

et al. 2024

Preprint

View full text Add to dashboard Cite

Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the USFDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. The article explores various vaccine candidates, including live attenuated, killed, nucleic-acid-based (DNA/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines emerge as promising candidates due to their rapid response capabilities and enhanced safety profile. The review underscores the importance of E1 and E2 proteins as immunogens, emphasising their antigenic potential. Several vaccine candidates, such as CHIKV/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical study results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates.

show abstract

Section: Immunology Of Chikungunya Virusmentioning

confidence: 99%

Chikungunya Virus Vaccine: An Update Review

Shaikh,

Faiyazuddin,

Khan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Cellular pathways and molecular events that shape autoantibody production in COVID-19

Tsay,

Zouali

2024

Journal of Autoimmunity

View full text Add to dashboard Cite

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions

Shaikh,

Faiyazuddin,

Khan

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the US FDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. This article explores various vaccine candidates, including live attenuated, killed, nucleic acid-based (DNA/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines have emerged as promising candidates due to their rapid response capabilities and enhanced safety profile. This review underscores the importance of the E1 and E2 proteins as immunogens, emphasizing their antigenic potential. Several vaccine candidates, such as CHIKV/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates. This article discusses potential antiviral targets, the significance of E1 and E2 proteins, monoclonal antibodies, and RNA vaccines as prospective Chikungunya virus vaccine candidates.

show abstract

Chikungunya virus and autoimmunity: Consensus immune epitope analysis between chikungunya virus and arthritis

Cited by 3 publications

References 9 publications

Chikungunya Virus Vaccine: An Update Review

Chikungunya Virus Vaccine: An Update Review

Cellular pathways and molecular events that shape autoantibody production in COVID-19

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions

Contact Info

Product

Resources

About